Filing search / Inhibrx Biosciences, Inc. / "Union"

DEFM14A

INBX Inhibrx Biosciences, Inc.

26 Apr 24

Proxy related to merger

4:06pm

of the Company or any Company Subsidiary is represented by any labor union, works council, employee representative group or similar organization (each … , a “Union”) with respect to his or her employment with the Company or any Company Subsidiary and (iv) no written demand has been made or petition has

DEFA14A

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Additional proxy soliciting materials

6:38am

of the Company or any Company Subsidiary is represented by any labor union, works council, employee representative group or similar organization (each … , a “Union”) with respect to his or her employment with the Company or any Company Subsidiary and (iv) no written demand has been made or petition has

8-K

EX-2.1

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

of the Company or any Company Subsidiary is represented by any labor union, works council, employee representative group or similar organization (each … , a “Union”) with respect to his or her employment with the Company or any Company Subsidiary and (iv) no written demand has been made or petition has

8-K

EX-10.1

INBX Inhibrx Biosciences, Inc.

29 Aug 23

Inhibrx Announces $200 Million Private Placement Financing

9:03am

Department (“OFAC”), the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority

8-K

EX-99.1

uy09smuov

7 Aug 23

Inhibrx Reports Second Quarter 2023 Financial Results

4:05pm

8-K

EX-10.1

5n8am70binn6nuy

4 Oct 22

Entry into a Material Definitive Agreement

8:02am

8-K

EX-99.1

9116chmdq5

15 Aug 22

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

4:09pm

8-K

EX-10.1

vgwtuw ptp

16 Jun 22

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-10.1

tjsf gry34zb

22 Feb 22

Inhibrx Announces Amended Loan Agreement with Oxford

9:11am

8-K

EX-99.1

fe5mhzhr7w6racsb

1 Dec 21

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

4:07pm

S-3ASR

EX-1.2

0jn edlqm

3 Sep 21

Automatic shelf registration

4:22pm

8-K

EX-10.1

wrd49w55ryg6 hkl

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.1

iz3e2kpr rj0p

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

10-K

283gnqcwlwvl4kc

12 Mar 21

Annual report

8:46am

10-Q

kmjv83n

13 Nov 20

Quarterly report

4:09pm

8-K

EX-99.1

i4ced

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am

424B4

i95ai 55l3

19 Aug 20

Prospectus supplement with pricing info

5:21pm